ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment N Li, Y Kang, L Wang, S Huff, R Tang, H Hui, K Agrawal, GM Gonzalez, ... Proceedings of the National Academy of Sciences 117 (33), 20159-20170, 2020 | 386 | 2020 |
m6A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy L Wang, H Hui, K Agrawal, Y Kang, N Li, R Tang, J Yuan, TM Rana The EMBO journal 39 (20), e104514, 2020 | 293 | 2020 |
HIV reprograms host m6Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1 Q Zhang, Y Kang, S Wang, GM Gonzalez, W Li, H Hui, Y Wang, TM Rana Nature communications 12 (1), 5543, 2021 | 34 | 2021 |
Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy Y Kang, S Vijay, TS Gujral Iscience 25 (5), 2022 | 8 | 2022 |
Subtype and Site Specific–Induced Metabolic Vulnerabilities in Prostate Cancer F Mossa, D Robesti, R Sumankalai, E Corey, M Titus, Y Kang, J Zhang, ... Molecular Cancer Research 21 (1), 51-61, 2023 | 7 | 2023 |
KIAA1429/VIRMA promotes breast cancer progression by m6A‐dependent cytosolic HAS2 stabilization N Li, Z Zhu, Y Deng, R Tang, H Hui, Y Kang, TM Rana EMBO reports 24 (10), e55506, 2023 | 2 | 2023 |
Single-cell Profiling Uncovers a Muc4-Expressing Metaplastic Gastric Cell Type Sustained by Helicobacter pylori-driven Inflammation VP O'Brien, Y Kang, MK Shenoy, G Finak, WC Young, J Dubrulle, L Koch, ... Cancer Research Communications 3 (9), 1756-1769, 2023 | 2 | 2023 |
Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation AT Olson, Y Kang, AM Ladha, S Zhu, CB Lim, B Nabet, M Lagunoff, ... PLoS Pathogens 19 (9), e1011169, 2023 | 2 | 2023 |
Transcriptional rewiring of BET inhibitor treated Ewing sarcoma cells augments their dependency on focal adhesion kinase SS Ganapathi, E Wrenn, N Garcia, N Katiyar, A Miyaki, Y Kang, M Chan, ... Cancer Research 84 (6_Supplement), 150-150, 2024 | | 2024 |
Integrating organotypic tissue slices and polypharmacology-based screening to map the toxicity landscape of kinase inhibitors Y Kang, M Chan, S Zhu, TS Gujral Cancer Research 84 (6_Supplement), 616-616, 2024 | | 2024 |
A kinase to cytokine explorer to identify molecular regulators and potential therapeutic opportunities M Chan, Y Kang, S Osborne, M Zager, TS Gujral Elife 12, RP91472, 2024 | | 2024 |
Impact of TP53 mutation on tumor microenvironment in HPV-HNSCC Y Kang Johns Hopkins University, 2021 | | 2021 |